Temporal evolution of biomarkers from healthy ageing, isolated REM sleep behavior to early Parkinson’s disease
Objective: To study the temporal evolution of biomarkers of various modalities in healthy ageing controls (HC), the prodromal condition of isolated REM sleep behavior disorder…GBA haploinsufficiency accelerated alpha synuclein pathology with altered lipid metabolism in a premotor model of Parkinson’s disease
Objective: To make Parkinson’s disease (PD) mice model and investigate the mechanism how glucocerebrosidase (gba) heterozygous mutations contribute to asyn pathology and development of PD.…Natural occurring antibodies reduce aggregation of α-synuclein
Objective: We tested naturally occurring antibodies (nAbs) against α-synuclein both in vitro as well as in HEK293T cells to determine binding, cell viability and capacity…Development of anti-amyloid drugs for Parkinson’s disease by combination screening of high-throughput in vitro assay and phenotype-based C. elegans system
Objective: To establish a new combination screening system consisted of high-throughput in vitro assay with phenotype-based in vivo assay and to develop anti-amyloid drugs truly…Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona
Objective: Determine prevalence of REM Sleep Behavior Disorder (RBD) in Sun City, Arizona Background: RBD is the strongest known clinical risk factor for neurodegenerative disorders…Predicting Alpha-Synuclein Pathology by REM Sleep Behavior Disorder Diagnosis
Objective: Determine sensitivity, specificity and predictive value of clinician diagnosed probable REM sleep behavior disorder (PRBD) in predicting alpha-synuclein pathology. Background: Inability to accurately diagnose…Longitudinal alpha-synuclein in cerebrospinal fluid in early Parkinson’s disease, prodromal PD and healthy controls
Objective: To examine the longitudinal relationships between total alpha-synuclein (aSyn) changes in cerebrospinal fluid (CSF), clinical measures, and factors that may influence CSF aSyn in…PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach
Objective: To evaluate the safety and tolerability of epigallocatechin gallate (EGCG) in high doses and its efficacy to slow down disease progression in patients with…Incidence, prevalence and clinical features of sleep disorders in alphasynucleinopthies: A cohort study
Objective: Analyze the sleep disorders incidence, prevelence an clinical features depending on the time of evolution, depending on the type of alpha-synuclein, and the subtype…Free-living gait in REM sleep behaviour disorder: Measures of prodromal Parkinson’s disease?
Objective: The aim of this study was to investigate if free-living gait monitoring can discriminate individuals with REM sleep behaviour disorder (RBD) from controls. Background:…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 18
- Next Page »
